Leak in blood-brain barrier linked to early Alzheimer's

Contrast enhanced MRI found leakages in the blood-brain barrier of people with early Alzheimer’s disease (AD) is associated with cognitive decline.

The study published in Radiology tested 16 patients with early AD and 17 healthy age-matched controls who underwent dynamic contrast material enhanced MRI. The researchers used the Paltak graphical approach to measure blood-brain barrier rate and volume.

Data suggested that the blood-brain barrier leakage rate in images were much higher in patients with AD compared to those without the disease, showing up most in the cerebrum. Patients with AD also had a significantly higher volume of leaking brain tissue in the gray matter, normal-appearing white matter and deep gray matter. 

"Blood-brain barrier leakage means that the brain has lost its protective means, the stability of brain cells is disrupted and the environment in which nerve cells interact becomes ill-conditioned," said study author Walter H. Backes, PhD, from the Maastricht University Medical Center in Maastricht, Netherlands. "These mechanisms could eventually lead to dysfunction in the brain."

The correlation between blood-brain barrier impairment and decline in cognitive performance that the researchers found, suggests that a leak in the blood-brain barrier is part of the early stages of AD and could eventually lead to cognitive decline and dementia.

"For Alzheimer's research, this means that a novel tool has become available to study the contribution of blood-brain barrier impairment in the brain to disease onset and progression in early stages or pre-stages of dementia," said Backes. 

 

Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.